Status:

COMPLETED

Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

Lead Sponsor:

Azienda Ospedaliera Universitaria Integrata Verona

Collaborating Sponsors:

Ospedale Mater Salutis-Legnago(Verona), Italy

Casa di Cura Dott. Pederzoli

Conditions:

Urothelial Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The goal of this observational study is to evaluate the clinical outcomes, side effects, and costs of Avelumab maintenance therapy in first-line and Pembrolizumab in second-line for platinum-fit patie...

Detailed Description

Retrospective-prospective study

Eligibility Criteria

Inclusion

  • At least 18 years of age
  • ECOG PS 0-2
  • Diagnosis of pathologically confirmed stage IV urothelial cancer, regardless of PD-L1 status
  • Patients treated with platinum-based chemotherapy (Cisplatin or Carboplatin) in the first-line setting who have not shown disease progression after 4-6 cycles of chemotherapy
  • Patients receiving Avelumab as maintenance therapy in the first-line setting or Pembrolizumab in the second-line setting
  • Availability of hospital and/or outpatient medical records for clinical data collection
  • Ability to understand and willingness to provide informed consent, or deceased patients at the time of enrollment, in compliance with Article 110 of the Privacy Code and the safeguards established by the Data Protection Authority in Provision No. 298 of May 9, 2024.

Exclusion

  • History of another malignancy or concurrent malignancy (except for cured non-melanoma skin cancer, low-risk prostate cancer, T1/T2 glottic cancer, stage 0 or I breast cancer, non-invasive bladder cancer, or in situ cervical cancer).

Key Trial Info

Start Date :

September 16 2024

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 22 2025

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT07207928

Start Date

September 16 2024

End Date

December 22 2025

Last Update

January 9 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Azienda Ospedaliera Universitaria Integrata di Verona

Verona, Verona, Italy, 37134

Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer. | DecenTrialz